Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

The projected decline in ZYDUSLIFE's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.88500
forwardPE 22.20791
debtToEquity 12.20900
earningsGrowth -0.00400
revenueGrowth 0.18000
grossMargins 0.71868
operatingMargins 0.29227
trailingEps 44.94000
forwardEps 0.00000

With a current ratio of 1.885, ZYDUSLIFE has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that ZYDUSLIFE is in a strong position to meet its immediate financial obligations without difficulty.
Zydus Lifesciences Limited's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
ZYDUSLIFE's low Debt-to-Equity ratio means it is not excessively leveraged, implying a reduced financial risk profile. This suggests ZYDUSLIFE maintains a well-balanced financial structure, with more emphasis on equity than debt, ensuring greater flexibility and long-term stability.
ZYDUSLIFE's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

ZYDUSLIFE's price projections have been revised downward over time, reflecting a shift in sentiment among analysts. The steady decline in projections points to a more cautious outlook on the company's future performance.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Analysts' buy bias toward Zydus Lifesciences Limited suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Zydus Lifesciences Limited is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.